CD19 and acquired idiopathic inflammatory myopathy: Overall, these results underscore the potential of Hu19-CD828Z CAR T-cells as a feasible and effective option for targeting CD19+ B-cells also in autoimmune diseases, like SLE, IIM, and SSc.